# OPTUMRX FORMULARY ANALYSIS: 2025 → 2026


Generated: 2025-12-23 20:04:33
Mode: pdf_direct
Source: optumrx_2025.pdf (60 pages)
        optumrx_2026.pdf (61 pages)

--------------------------------------------------------------------------------

# OptumRx Formulary Comparison: 2025 vs 2026

## Executive Summary

The 2026 OptumRx Premium Formulary shows significant strategic shifts including expanded biosimilar coverage, new specialty drug additions, notable tier movements, and continued emphasis on generic utilization. Key themes include new Alzheimer's disease treatments, expanded atopic dermatitis options, and restructured ADHD coverage.

---

## 1. Drug Additions (New in 2026)

### High-Impact New Additions

| Drug Name    | Therapeutic Class       | Tier   | Restrictions | Clinical Significance                      |
| ------------ | ----------------------- | ------ | ------------ | ------------------------------------------ |
| **KISUNLA**  | Alzheimer's Disease     | Tier 3 | SP           | New anti-amyloid monoclonal antibody       |
| **LEQEMBI**  | Alzheimer's Disease     | Tier 3 | SP           | Moved from Excluded to Covered             |
| **JOURNAVX** | Pain (Non-Opioid)       | Tier 3 | QL           | Novel non-opioid analgesic                 |
| **ZURZUVAE** | Depression (Postpartum) | Tier 3 | PA, QL       | First oral postpartum depression treatment |
| **AUVELITY** | Depression              | Tier 3 | ------------ | Moved from Excluded to Covered             |
| **ZEPBOUND** | Diabetes/Weight Loss    | Tier 3 | PA, QL       | Tirzepatide for chronic weight management  |
| **NEFFY**    | Anaphylaxis             | Tier 2 | ------------ | Needle-free epinephrine nasal spray        |
| **TZIELD**   | Type 1 Diabetes         | Tier 3 | PA, SP       | First disease-modifying T1D therapy        |

### New Biosimilars Added

| Biosimilar    | Reference Product | Tier   | Notes                                 |
| ------------- | ----------------- | ------ | ------------------------------------- |
| **CYLTEZO**   | Humira            | Tier 2 | PA, SP - Expanded adalimumab options  |
| **HADLIMA**   | Humira            | Tier 2 | PA, SP - Additional biosimilar choice |
| **AVSOLA**    | Remicade          | Tier 2 | PA, SP - Infliximab biosimilar        |
| **TRAZIMERA** | Herceptin         | Tier 2 | PA, SP - Oncology biosimilar          |
| **ZIRABEV**   | Avastin           | Tier 2 | PA, SP - Oncology biosimilar          |

### New Specialty/Rare Disease Additions

| Drug         | Condition                   | Tier   | Restrictions |
| ------------ | --------------------------- | ------ | ------------ |
| **BIMZELX**  | Psoriasis/PsA               | Tier 3 | PA, SP, QL   |
| **EBGLYSS**  | Atopic Dermatitis           | Tier 2 | PA, SP, QL   |
| **NEMLUVIO** | Atopic Dermatitis           | Tier 3 | PA, SP, QL   |
| **ADBRY**    | Atopic Dermatitis           | Tier 2 | PA, SP, QL   |
| **LITFULO**  | Alopecia Areata             | Tier 3 | PA, SP, QL   |
| **IQIRVO**   | Primary Biliary Cholangitis | Tier 3 | PA, SP, QL   |
| **LIVDELZI** | Primary Biliary Cholangitis | Tier 3 | PA, SP, QL   |
| **CAMZYOS**  | Hypertrophic Cardiomyopathy | Tier 3 | ------------ |
| **LEQVIO**   | Hyperlipidemia (siRNA)      | Tier 3 | ------------ |
| **LODOCO**   | Cardiovascular (Colchicine) | Tier 3 | ------------ |

### New Generics Added

| Generic Drug              | Therapeutic Class | Tier   | Previous Status          |
| ------------------------- | ----------------- | ------ | ------------------------ |
| **budesonide-formoterol** | Asthma/COPD       | Tier 1 | New generic availability |
| **tiotropium bromide**    | COPD              | Tier 1 | New generic availability |
| **icosapent ethyl**       | Cardiovascular    | Tier 1 | Generic Vascepa          |
| **lisdexamfetamine**      | ADHD              | Tier 1 | Generic Vyvanse          |
| **abiraterone acetate**   | Oncology          | Tier 1 | Generic Zytiga           |
| **lenalidomide**          | Oncology          | Tier 1 | Generic Revlimid         |
| **dexlansoprazole**       | GERD              | Tier 1 | Generic Dexilant         |

---

## 2. Drug Removals (Excluded in 2026)

### Significant Removals from Coverage

| Drug              | Therapeutic Class           | 2025 Status | 2026 Status | Impact                                     |
| ----------------- | --------------------------- | ----------- | ----------- | ------------------------------------------ |
| **AJOVY**         | Migraine Prevention         | Tier 2      | Excluded    | High - CGRP option removed                 |
| **STELARA**       | Immunology/IBD              | Tier 2      | Excluded    | Very High - Major biologic                 |
| **NAMZARIC**      | Alzheimer's                 | Tier 2      | Excluded    | Moderate - Combination product             |
| **AUBAGIO**       | Multiple Sclerosis          | Tier 2      | Excluded    | High - Oral MS therapy                     |
| **COPAXONE 40mg** | Multiple Sclerosis          | Tier 2      | Excluded    | Moderate - Generic available               |
| **TECFIDERA**     | Multiple Sclerosis          | Tier 2      | Excluded    | High - Generic dimethyl fumarate preferred |
| **GILENYA**       | Multiple Sclerosis          | Tier 3      | Excluded    | High - Oral MS therapy                     |
| **PLEGRIDY**      | Multiple Sclerosis          | Tier 3      | Excluded    | Moderate                                   |
| **REBIF**         | Multiple Sclerosis          | Tier 3      | Excluded    | Moderate                                   |
| **MOVANTIK**      | Opioid-Induced Constipation | Tier 2      | Excluded    | Moderate - SYMPROIC preferred              |
| **TRULANCE**      | IBS-C/CIC                   | Tier 2      | Excluded    | Moderate - LINZESS preferred               |
| **DEXILANT**      | GERD                        | Tier 2      | Excluded    | Low - Generic available                    |
| **GLEEVEC**       | Oncology                    | Tier 2      | Excluded    | Low - Generic imatinib available           |
| **SPRYCEL**       | Oncology                    | Tier 2      | Excluded    | Moderate                                   |
| **ZYTIGA**        | Oncology                    | Tier 3      | Excluded    | Low - Generic abiraterone available        |

### Brand-to-Generic Transitions (Brands Now Excluded)

| Brand Removed    | Generic Alternative | Tier   |
| ---------------- | ------------------- | ------ |
| TAMIFLU          | oseltamivir         | Tier 1 |
| VALTREX          | valacyclovir        | Tier 1 |
| LUNESTA          | eszopiclone         | Tier 1 |
| RESTORIL         | temazepam           | Tier 1 |
| NUVIGIL/PROVIGIL | modafinil           | Tier 1 |

---

## 3. Tier Changes

### Drugs Moving to Higher Tiers (Increased Cost)

| Drug          | 2025 Tier | 2026 Tier | Change      | Likely Reason                               |
| ------------- | --------- | --------- | ----------- | ------------------------------------------- |
| **SYMBICORT** | Tier 1    | Tier 3    | ↑2 tiers    | Generic budesonide-formoterol now available |
| **ZEPBOUND**  | Tier 2    | Tier 3    | ↑1 tier     | Cost management for weight loss             |
| **VYVANSE**   | Tier 2    | Tier 3    | ↑1 tier     | Generic lisdexamfetamine available          |
| **LYBALVI**   | Excluded  | Tier 3    | Now covered | New coverage with restrictions              |
| **DESCOVY**   | Excluded  | Tier 3    | Now covered | HIV PrEP option added                       |

### Drugs Moving to Lower Tiers (Decreased Cost)

| Drug         | 2025 Tier          | 2026 Tier         | Change               | Likely Reason                  |
| ------------ | ------------------ | ----------------- | -------------------- | ------------------------------ |
| **BIKTARVY** | Tier 3             | Tier 2            | ↓1 tier              | Preferred HIV regimen          |
| **CABENUVA** | Not listed         | Tier 2            | New addition         | Long-acting HIV option         |
| **REPATHA**  | Tier 2 (PA)        | Tier 2 (ST)       | Restriction change   | Step therapy vs PA             |
| **DUPIXENT** | Tier 2 (Derm only) | Tier 2 (expanded) | Expanded indications | Now in respiratory section too |

### ADHD Category Restructuring

| Drug                 | 2025 Status          | 2026 Status     | Notes                                |
| -------------------- | -------------------- | --------------- | ------------------------------------ |
| **lisdexamfetamine** | Brand only (VYVANSE) | Tier 1 generic  | Major cost savings                   |
| **VYVANSE**          | Tier 2               | Tier 3 (ST, QL) | Step therapy now required            |
| **CONCERTA**         | Tier 2               | Excluded        | Generic methylphenidate ER preferred |
| **ADDERALL XR**      | Tier 2               | Excluded        | Generic amphetamine salts preferred  |
| **QELBREE**          | Tier 2/3             | Excluded        | Non-stimulant removed                |
| **AZSTARYS**         | Not listed           | Tier 2 (ST, QL) | New branded option                   |
| **JORNAY PM**        | Not listed           | Tier 3 (ST, QL) | Evening-dosed option added           |

---

## 4. Restriction Changes

### New Prior Authorization Requirements

| Drug         | 2025 Restrictions | 2026 Restrictions | Change     |
| ------------ | ----------------- | ----------------- | ---------- |
| **NURTEC**   | QL only           | PA, QL            | PA added   |
| **UBRELVY**  | QL only           | PA, QL            | PA added   |
| **QULIPTA**  | QL only           | PA, QL            | PA added   |
| **AIMOVIG**  | PA, SP, QL        | PA, QL            | SP removed |
| **EMGALITY** | PA, SP, QL        | PA, QL            | SP removed |
| **VASCEPA**  | Not listed        | PA                | PA added   |

### New Step Therapy Requirements

| Drug          | 2025 Restrictions | 2026 Restrictions | Impact                            |
| ------------- | ----------------- | ----------------- | --------------------------------- |
| **REPATHA**   | PA, QL            | ST, QL            | Must try statin + ezetimibe first |
| **LINZESS**   | None              | ST, QL            | Must try other agents first       |
| **SYMBICORT** | QL                | ST, QL            | Must try generic ICS/LABA first   |
| **VYVANSE**   | None              | ST, QL            | Must try generic stimulants first |
| **EUCRISA**   | None              | ST                | Must try other topicals first     |
| **OPZELURA**  | None              | ST, QL            | Must try other agents first       |
| **VTAMA**     | Not listed        | ST                | Step therapy for psoriasis        |

### Quantity Limit Changes

| Drug               | 2025 QL | 2026 QL    | Notes           |
| ------------------ | ------- | ---------- | --------------- |
| **HAEGARDA**       | PA, SP  | PA, SP, QL | QL added        |
| **TAKHZYRO**       | PA, SP  | PA, SP, QL | QL added        |
| **Multiple CGRPs** | QL      | PA, QL     | PA added to all |

### Specialty Designation Changes

| Drug                  | 2025       | 2026       | Change                        |
| --------------------- | ---------- | ---------- | ----------------------------- |
| **AIMOVIG**           | SP         | Non-SP     | Removed specialty designation |
| **EMGALITY**          | SP         | Non-SP     | Removed specialty designation |
| **dalfampridine er**  | PA, SP, QL | PA, SP, QL | Now Tier 1 generic            |
| **dimethyl fumarate** | PA, SP, QL | PA, SP, QL | Now Tier 1 generic            |

---

## 5. Biosimilar/Generic Strategy Changes

### Expanded Adalimumab Biosimilar Options

| Biosimilar   | 2025 Status      | 2026 Status      |
| ------------ | ---------------- | ---------------- |
| **AMJEVITA** | Tier 2 Preferred | Tier 2 Preferred |
| **CYLTEZO**  | Excluded         | Tier 2 Covered   |
| **HADLIMA**  | Excluded         | Tier 2 Covered   |
| **ABRILADA** | Excluded         | Excluded         |
| **HYRIMOZ**  | Excluded         | Excluded         |
| **YUFLYMA**  | Excluded         | Excluded         |

### New Generic Availability Impact

| Brand         | Generic               | 2026 Generic Tier | Brand Status |
| ------------- | --------------------- | ----------------- | ------------ |
| **Symbicort** | budesonide-formoterol | Tier 1            | Tier 3       |
| **Spiriva**   | tiotropium bromide    | Tier 1            | Tier 2       |
| **Vyvanse**   | lisdexamfetamine      | Tier 1            | Tier 3       |
| **Vascepa**   | icosapent ethyl       | Tier 1            | Tier 2       |
| **Dexilant**  | dexlansoprazole       | Tier 1            | Excluded     |
| **Revlimid**  | lenalidomide          | Tier 1            | Tier 2       |
| **Zytiga**    | abiraterone acetate   | Tier 1            | Excluded     |
| **Tecfidera** | dimethyl fumarate     | Tier 1            | Excluded     |

### Infliximab Biosimilar Strategy

| Product       | 2025                  | 2026         |
| ------------- | --------------------- | ------------ |
| **INFLECTRA** | Tier 2                | Tier 2       |
| **AVSOLA**    | Not listed            | Tier 2 (New) |
| **REMICADE**  | Not explicitly listed | Excluded     |

---

## 6. Therapeutic Class Changes

### Alzheimer's Disease - Major Expansion

| Drug          | 2025     | 2026       | Notes               |
| ------------- | -------- | ---------- | ------------------- |
| **donepezil** | Tier 1   | Tier 1     | Unchanged           |
| **memantine** | Tier 1   | Tier 1     | Unchanged           |
| **NAMZARIC**  | Tier 2   | Excluded   | Combination removed |
| **ADUHELM**   | Excluded | Not listed | Removed entirely    |
| **LEQEMBI**   | Excluded | Tier 3 SP  | Now covered         |
| **KISUNLA**   | N/A      | Tier 3 SP  | New addition        |

### Multiple Sclerosis - Significant Restructuring

**Removed from Coverage:**
- AUBAGIO
- COPAXONE 40mg
- TECFIDERA (brand)
- GILENYA
- PLEGRIDY
- REBIF

**Retained/Added:**
- dimethyl fumarate (generic) - Tier 1
- KESIMPTA - Tier 2 (preferred)
- VUMERITY - Tier 2
- MAVENCLAD, MAYZENT, PONVORY, ZEPOSIA - Tier 3

### Atopic Dermatitis - Expanded Options

| Drug         | 2025       | 2026            | Notes              |
| ------------ | ---------- | --------------- | ------------------ |
| **DUPIXENT** | Tier 2     | Tier 2          | Remains preferred  |
| **EUCRISA**  | Tier 2     | Tier 2 (ST)     | Step therapy added |
| **OPZELURA** | Tier 2     | Tier 3 (ST, QL) | Higher tier + ST   |
| **CIBINQO**  | Tier 2     | Tier 3          | Higher tier        |
| **ADBRY**    | Not listed | Tier 2          | New addition       |
| **EBGLYSS**  | Not listed | Tier 2          | New addition       |
| **NEMLUVIO** | Not listed | Tier 3          | New addition       |

### Weight Management - Restructured

| Drug            | 2025        | 2026        | Notes          |
| --------------- | ----------- | ----------- | -------------- |
| **phentermine** | Tier 1 (++) | Tier 1 (++) | Unchanged      |
| **QSYMIA**      | Tier 2      | Not listed  | Removed        |
| **SAXENDA**     | Tier 2      | Not listed  | Removed        |
| **WEGOVY**      | Tier 2      | Not listed  | Not in summary |
| **ZEPBOUND**    | Tier 2      | Tier 3      | Higher tier    |
| **CONTRAVE**    | Excluded    | Excluded    | Unchanged      |

### Migraine - CGRP Class Changes

| Drug         | 2025                | 2026            | Change           |
| ------------ | ------------------- | --------------- | ---------------- |
| **AIMOVIG**  | Tier 2 (PA, SP, QL) | Tier 2 (PA, QL) | SP removed       |
| **AJOVY**    | Tier 2 (PA, SP, QL) | Excluded        | Removed          |
| **EMGALITY** | Tier 2 (PA, SP, QL) | Tier 2 (PA, QL) | SP removed       |
| **NURTEC**   | Tier 2 (QL)         | Tier 2 (PA, QL) | PA added         |
| **UBRELVY**  | Tier 2 (QL)         | Tier 2 (PA, QL) | PA added         |
| **QULIPTA**  | Tier 2 (QL)         | Tier 2 (PA, QL) | PA added         |
| **ZAVZPRET** | Not listed          | Tier 3 (PA, QL) | New nasal option |
| **REYVOW**   | Not listed          | Tier 3          | New addition     |

---

## 7. Financial Impact Summary

### Estimated Member Cost Impact

| Category        | Direction  | Affected Drugs                            | Member Impact              |
| --------------- | ---------- | ----------------------------------------- | -------------------------- |
| **ADHD**        | ↓ Cost     | Generic lisdexamfetamine                  | Significant savings        |
| **Asthma/COPD** | ↓ Cost     | Generic budesonide-formoterol, tiotropium | Significant savings        |
| **MS**          | ↓ Cost     | Generic dimethyl fumarate                 | Moderate savings           |
| **Oncology**    | ↓ Cost     | Generic abiraterone, lenalidomide         | Significant savings        |
| **Migraine**    | ↑ Barriers | PA added to acute treatments              | More administrative burden |
| **Weight Loss** | ↑ Cost     | ZEPBOUND to Tier 3                        | Higher copays              |
| **Alzheimer's** | New Access | LEQEMBI, KISUNLA covered                  | New treatment options      |

### Plan Cost Management Strategies Observed

1. **Generic Maximization**: Aggressive movement to generics when available
2. **Biosimilar Expansion**: More adalimumab and infliximab options
3. **Step Therapy Expansion**: More drugs require trying alternatives first
4. **PA Tightening**: Additional PA requirements on high-cost drugs
5. **Therapeutic Consolidation**: Fewer options per class, clear preferences

---

## 8. Key Recommendations for Stakeholders

### For Prescribers

1. **MS Patients**: Transition patients on AUBAGIO, TECFIDERA (brand), GILENYA to covered alternatives
2. **Migraine Patients**: Prepare PA documentation for CGRP medications
3. **ADHD Patients**: Consider generic lisdexamfetamine before brand VYVANSE
4. **Alzheimer's Patients**: New options LEQEMBI and KISUNLA now available

### For Pharmacists

1. **Generic Substitution**: New generics for budesonide-formoterol, tiotropium, lisdexamfetamine
2. **Biosimilar Counseling**: Expanded adalimumab biosimilar options
3. **PA Workflows**: Update for new CGRP PA requirements

### For Plan Sponsors

1. **Cost Savings Opportunities**: Generic ADHD, respiratory, and MS drugs
2. **Specialty Spend**: Monitor new Alzheimer's drug utilization
3. **Utilization Management**: Enhanced step therapy may reduce costs

---

## Appendix: Complete Change Summary Tables

### Additions Summary
- **New Molecular Entities**: 15+
- **New Biosimilars**: 5
- **New Generics**: 7+
- **Moved from Excluded to Covered**: 4

### Removals Summary
- **Moved to Excluded**: 20+
- **Brand-to-Generic Transitions**: 10+

### Restriction Changes Summary
- **New PA Requirements**: 8+
- **New Step Therapy**: 10+
- **New Quantity Limits**: 5+

---

*Analysis completed based on formulary documents dated January 1, 2025 and January 1, 2026*